Chemoinformatics in Lead Discovery

Chemoinformatics in Drug Discovery

Volumn 23, Issue , 2005, Pages 23-41

  Oprea, Tudor I ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoinformatics in lead discovery; Pharmaceutical research

Indexed keywords

CHEMOINFORMATICS; DRUG DISCOVERY; HIGH ACTIVITY; PHARMACEUTICAL RESEARCH;

EID: 85019822664     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527603743.ch2     Document Type: Chapter

References (76)

1. WEININGER, D. Combinatorics of small molecular structures. In Encyclopedia of Computational Chemistry, Vol. 1, VON RAGUÉ SCHLEYER, P., ALLINGER, N.L., CLARK, T., GASTEIGER, J., KOLLMAN, P.A., SCHAEFER III, H.F. (eds.) Wiley, New York, 1998, 425-430.
2. HORROBIN, D.F. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat. Rev. Drug Disc. 2003, 2, 151-154.
3. DEFELICE, S.L. Drug Discovery - The Pending Crisis. MEDCOM, New York, 1972.
4. OPREA, T.I., MATTER, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 2004, 8, 349-358.
5. OPREA, T.I. Virtual screening in lead discovery: a viewpoint. Molecules 2002, 7, 51-62.
6. DREWS, J. Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D. Drug Discovery Today 1998, 3, 491-494.
7. LIPINSKI, C.A. Technical and people disconnects hindering knowledge exchange between chemistry and biology. 227th ACS National Meeting, Anaheim, CA, 2004, CINF-009.
8. OLSSON, T., OPREA, T.I. Cheminformatics: a tool for decision-makers in drug discovery. Curr. Opin. Drug. Disc. Dev. 2001, 4, 308-313.
9. BROWN, F. Chemoinformatics: What is it and How does it impact drug discovery. Annu. Rep. Med. Chem. 1998, 33, 375-384.
10. HAHN, M.M., GREEN, R. Cheminformatics - a new name for an old problem? Curr. Opin. Chem. Biol. 1999, 3, 379-383.
11. ERHARDT, W.P. Medicinal chemistry in the new millennium. A glance into the future. Pure Appl. Chem. 2002, 74, 703-785.
12. OPREA, T.I. Lead structure searching: are we looking for the appropriate properties? J. Comput.-Aided Mol. Des. 2002, 16, 325-334.
13. RISHTON, G.M. Reactive compounds and in vitro false positives in HTS. Drug Discovery Today 1997, 2, 382-384.
14. RISHTON, G.M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today 2003, 8, 86-96.
15. MCGOVERN, S.L., CASELLI, E., GRIGORIEFF, N., SHOICHET, B.K. A common mechanism underlying promiscuous inhibitors from virtual and highthroughput screening. J. Med. Chem. 2002, 45, 1712-1722.
16. ROCHE, O., SCHNEIDER, P., ZUEGGE, J., GUBA, W., KANSY, M., ALANINE, A., BLEICHER, K., DANEL, F., GUTKNECHT, E.M., ROGERS-EVANS, M., NEIDHART, W., STALDER, H., DILLON, M., SJOEGREN, E., FOTOUHI, N., GILLESPIE, P., GOODNOW, R., HARRIS, W., JONES, P., TANIGUCHI, M., TSUJII, S., VON SAAL, W., ZIMMERMANN, G., SCHNEIDER, G. Development of a virtual screening method for identification of ''frequent hitters'' in compound libraries. J. Med. Chem. 2002, 45, 137-142.
17. SEIDLER, J., MCGOVERN, S.L., DOMAN, T., SHOICHET, B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
18. DESTEVENS, G. Serendipity and structured research in drug discovery. Prog. Drug. Res. 1986, 30, 189-203.
19. SNEADER, W. Drug Prototypes and their Exploitation. Wiley, Chichester, UK, 1996.
20. BOYD, D.B. Progress in rational design of therapeutically interesting compounds. In Rational Molecular Design in Drug Research, LILJEFORS, T., JORGENSEN, F.S., KROGSGAARD-LARSEN, P. (eds.) Munksgaard, Copenhagen, 1998, 15-29.
21. KENNEDY, T. Managing the drug discovery/development interface. Drug Discov. Today 1997, 2, 436-444.
22. PROUDFOOT, J.R. Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. 2002, 12, 1647-1650.
23. LIPINSKI, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
24. MEYLAN, W.M., HOWARD, P.H. Atom/fragment contribution method for estimating octanol-water partition coefficients. J. Pharm. Sci. 1995, 84, 83-92; KOWWIN is available from http://www.epa.gov/oppt/exposure/docs/episuitedl.htm.
25. MEYLAN, W.M., HOWARD, P.H., BOETHLING, R.S. Improved method for estimating water solubility from octanol/water partition coefficient. Environ. Toxicol. Chem. 1996, 15, 100-106; WSKOWIN is available from http://www.epa.gov/oppt/exposure/docs/episuitedl.htm.
26. OLAH, M., MRACEC, M., OSTOPOVICI, L., RAD, R., BORA, A., HADARUGA, N., OLAH, I., BANDA, M., SIMON, Z., MRACEC, M., OPREA, T.I. WOMBAT: World of molecular bioactivity. In Chemoinformatics in Drug Discovery, OPREA, T.I. (ed.) Wiley-VCH, Weinheim, 2004, 223-239.
27. WOMBAT 2004.1 is available from Sunset Molecular Discovery, Santa Fe, New Mexico, http://www.sunsetmolecular.com and from Metaphorics LLC, Santa Fe, New Mexico, 2004, http://www.metaphorics.com.
28. LEO, A., WEININGER, D. CMR3. Available from Daylight Chemical Information Systems, Santa Fe, New Mexico, 2004, http://www.daylight.com/
29. OPREA, T.I. Property distribution of drug-related chemical databases. J. Comput.-Aided Mol. Des. 2000, 14, 251-264.
30. LEO, A. Estimating LogPoct from structures. Chem. Rev. 1993, 5, 1281-1306.
31. LEO, A., WEININGER, D. ClogP 4.0. Available from Daylight Chemical Information Systems, Santa Fe, New Mexico, 2004, http://www.daylight.com/
32. RAN, Y., JAIN, N., YALKOWSKY, S.H. Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE). J. Chem. Inf. Comput. Sci. 2001, 41, 1208-1217.
33. LIVINGSTONE, D.J., FORD, M.G., HUUSKONEN, J.J., SALT, D.W. Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure. J. Comput. Aided Mol. Des. 2001, 15, 741-752.
34. OPREA, T.I. Rapid estimation of hydrophobicity for virtual combinatorial library analysis. SAR and QSAR Environ. Res. 2001, 12, 129-141.
35. LIPINSKI, C.A., LOMBARDO, F., DOMINY, B.W., FEENEY, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25.
36. WDI, the Derwent World Drug Index, is available from Daylight Chemical Information Systems, 2004, http://www.daylight.com/
37. ANDREWS, P.R., CRAIK, D.J., MARTIN, J.L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27, 1648-1657.
38. TEAGUE, S.J., DAVIS, A.M., LEESON, P.D., OPREA, T.I. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. 1999, 38, 3743-3748; German version: Angew. Chem. 1999, 111, 3962-3967.
39. GOODNOW, R.A., Jr, GILLESPIE, P., BLEICHER, K. Chemoinformatic tools for library design and the hit-to-lead process: a user's perspective. In Chemoinformatics in Drug Discovery, OPREA, T.I. (ed.) Wiley-VCH, Weinheim, 2004, 381-435.
40. KUNTZ, I.D., CHEN, K., SHARP, K.A., KOLLMAN, P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002.
41. PEARLMAN, R.S., SMITH, K.M. Novel software tools for chemical diversity. Perspect. Drug Disc. Des. 1998, 9-11, 339-353.
42. GODDEN, J.W., XUE, L., BAJORATH, J. Classification of biologically active compounds by median partitioning. J. Chem. Inf. Comput. Sci. 2002, 42, 1263-1269.
43. MDDR and ACD are available from MDL Information Systems, http://www.mdli.com/products/finders/databasefinder/ MDDR is developed in cooperation with Prous Science Publishers, 2004, http://www.prous.com/index.html.
44. HANN, M.M., OPREA, T.I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 2004, 8, 255-263.
45. HANN, M.M., LEACH, A., GREEN, D.V.S. Computational chemistry, molecular complexity and screening set design. In Chemoinformatics in Drug Discovery, OPREA, T.I. (ed.) Wiley-VCH, Weinheim, 2004, 43-57.
46. BINDRA, J.S., LEDNICER D. (eds.) Chronicles of Drug Discovery, Vol. 1. Wiley-Interscience, New York, 1982.
47. BINDRA, J.S., LEDNICER D. (eds.) Chronicles of Drug Discovery, Vol. 2. Wiley-Interscience, New York, 1983.
48. LEDNICER, D. (ed.) Chronicles of Drug Discovery, Vol. 3. ACS Publishers, Washington, DC, 1993.
49. BORCHARDT, R.T., FREIDINGER, R.M., SAWYER, T.K., SMITH, P.L. (eds.) Integration of Pharmaceutical Discovery and Development: Case Histories. Plenum Press, New York, 1998.
50. HORROBIN, D.F. Innovation in the pharmaceutical industry. J. R. Soc. Med. 2000, 93, 341-345.
51. ANON, Speed to value. Accenture Report, 2000, 23.
52. AJAY, WALTERS, W.P., MURCKO, M.A. Can we learn to distinguish between ''drug-like'' and ''nondrug-like'' molecules? J. Med. Chem. 1998, 41, 3314-3324.
53. SADOWSKI, J., KUBINYI, H.A. Scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
54. WAGENER, M., VAN GEERENSTEIN, V.J. Potential drugs and nondrugs: prediction and identification of important structural features. J. Chem. Inf. Comput. Sci. 2000, 40, 280-292.
55. FRIMURER, T.M., BYWATER, R., NAERUM, L., LAURITSEN, L.N., BRUNAK, S. Improving the odds in discriminating ''druglike'' from ''nondruglike'' compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 1315-1324.
56. BRÜSTLE, M., BECK, B., SCHINDLER, T., KING, W., MITCHELL, T., CLARK, T. Descriptors, physical properties and drug-likeness. J. Med. Chem. 2002, 45, 3345-3355.
57. VIETH, M., SIEGEL, M.G., HIGGS, R.E., WATSON, I.A., ROBERTSON, D.H., SAVIN, K.A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem. 2004, 47, 224-232.
58. HANN, M.M., LEACH, A.R., HARPER, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
59. OPREA, T.I., DAVIS, A.M., TEAGUE, S.J., LEESON, P.D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
60. DAVIS, A.M., TEAGUE, S.J., KLEYWEGT, G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem., Int. Ed. 2003, 42, 2718-2736; German edition: Angew. Chem. 2003, 115, 2822-2841.
61. KENAKIN, T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat. Rev. Drug Disc. 2003, 2, 429-438.
62. OPREA, T.I. Cheminformatics and the quest for leads in drug discovery. In Handbook of Cheminformatics, Vol. 4, GASTEIGER, J., ENGEL, T. (eds.) VCH-Wiley, New York, 2003, 1508-1531.
63. The list of drugs to be discontinued is continuously updated at the US Food and Drug Administration website, 2004, http://www.fda.gov/cder/drug/shortages/#disc
64. Orlaam(tm) (Levomethadyl hydrochloride acetate) was discontinued in the spring of 2004 because it caused severe cardiac toxicity, including Q-T prolongation, Torsade des pointes and cardiac arrest. See http://www.fda.gov/cder/drug/shortages/orlaam.htm.
65. Baycol(tm) was voluntarily withdrawn by Bayer in August 2001 because of reports of sometimes fatal rhabdomyolysis (a severe muscle averse reaction). See http://www.fda.gov/cder/drug/infopage/baycol/default.htm.
66. Redux(tm) and Pondimin(tm) were voluntarily withdrawn in September 1997 because 30% of the patients taking these two drugs had abnormal echocardiograms, 2004. See http://www.fda.gov/cder/news/phen/fenphenpr81597.htm.
67. HEAD, R.D., SMYTHE, M.L., OPREA, T.I., WALLER, C.L., GREEN, S.M., MARSHALL, G.R. VALIDATE: a new method for the receptor-based prediction of binding affinities of novel ligands. J. Am. Chem. Soc. 1996, 118, 3959-3969.
68. DAVIS, A.M., TEAGUE, S.J. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem., Int. Ed. 1999, 38, 736-749; German edition: Angew. Chem. 1999, 111, 778-792.
69. HANSCH, C., HOEKMAN, D., LEO, A., WEININGER, D., SELASSIE, C.D. Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology. Chem. Rev. 2002, 102, 783-812.
70. HANSCH, C., HOEKMAN, D., LEO, A., WEININGER, D., SELASSIE, C.D. C-QSAR Database. Available from the BioByte Corporation, Claremont, CA, 2004, http://www.biobyte.com/
71. HANSCH, C., FUJITA, T. ρ-σ-π analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86, 1616-1626.
72. OPREA, T.I. 3D-QSARmodeling in drug design. In Computational Medicinal Chemistry and Drug Discovery, TOLLENAERE, J., DE WINTER, H., LANGENAEKER, W., BULTINCK, P. (eds.) Marcel Dekker, New York, 2004, 571-616.
73. OLAH, M., BOLOGA, C., OPREA, T.I. An automated PLS search for biologicallyrelevant QSAR descriptors. Perspect. Drug Disc. Des., 2004 in press.
74. OPREA, T.I., BOLOGA, C., OLAH, M. Compound selection for virtual screening. In Virtual Screening in Drug Discovery, ALVAREZ, J.C., SHOICHET, B. (eds.) CRC Press, Boca Raton, 2005, in press.
75. VANDENBERG, J.I., WALKER, B.D., CAMPBELL, T.J. HERG K+ channels: friend or foe. Trends Pharm. Sci. 2001, 22, 240-246.
76. OPREA, T.I., LI, J., MURESAN, S., MATTES, K.C. High throughput and virtual screening: choosing the appropriate leads. In EuroQSAR 2002 - Designing drugs and crop protectants: Processes, problems and solutions, FORD, M., LIVINGSTONE, D., DEARDEN, J., VAN de WATERBEEMD, H. (eds.) Blackwell Publishing, New York, 2003, 40-47.